Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Guadecitabine in combination with pembrolizumab is tolerable with biological and anticancer activity. Reversal of previous resistance to immune checkpoint inhibitors is demonstrated.

Me gusta

Guardar

Ver artículo completo

Me gusta

Guardar

Ver artículo completo

Cite This Study

Papadatos-Pastos et al. (Wed,) studied this question.

synapsesocial.com/papers/69d9d6b184371aa676a3c01d https://doi.org/https://doi.org/10.1136/jitc-2022-004495